Development and validation of HPLC and UV spectrophotometric methods for the determination of lumiracoxib in tablets

In this study, two methods, based on highperformance liquid chromatography (HPLC) and UV spectrophotometry, were developed and validated for the quantitative determination of lumiracoxib in tablets. The HPLC was carried out on a column of propylsulfonic acid bonded to silica gel (250 x 4.6 mm; 5 μm), with a mobile phase of phosphate buffer (pH 7.4; 10 mM)-water-acetonitrile (10:40:50, v/v/v) fl owing at 1.0 mL/min and detection of the drug at 278 nm. The UV method was based on absorbance at 275 nm, with ethanol as solvent. Both assays were linear over the concentration range of 2–30 μg/mL (R≈0.999), as well as accurate and precise, with recoveries between 98 and 100% and relative standard deviation (%RSD) < 2.0%. The proposed methods are highly sensitive, precise and accurate and were successfully applied to the quantitation of lumiracoxib in the commercial formulation. The spectrophotometric method is a simple, cheap and less time-consuming method. However, the chromatographic method is selective for the determination of the degradation products of lumiracoxib. Keywords: lumiracoxib; tablets; HPLC; UV spectrophotometry; pharmaceutical analyses.

[1]  M. S. Sangoi,et al.  Determination of lumiracoxib by a validated stability-indicating MEKC method and identification of its degradation products by LC-ESI-MS studies. , 2011, Journal of separation science.

[2]  R. Moskowitz,et al.  Coxibs and NSAIDs--is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. , 2007, Osteoarthritis and cartilage.

[3]  P. Tugwell,et al.  Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Z. Radi,et al.  Effects of cyclooxygenase inhibition on the gastrointestinal tract. , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[5]  G. Geisslinger,et al.  Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. , 2006, Biochemical and biophysical research communications.

[6]  Anna Georgieva,et al.  Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.

[8]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[9]  K. Lasseter,et al.  No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. , 2004, Pharmacological research.

[10]  T. Tsuchiya,et al.  Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. , 2004, Biochemical pharmacology.

[11]  L. Laine,et al.  Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. , 2003, Gastroenterology.

[12]  L. Laine.  Gastrointestinal effects of NSAIDs and coxibs. , 2003, Journal of pain and symptom management.

[13]  G. Burmester,et al.  Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. , 2001, The American journal of medicine.

[14]  K. Rainsford.  Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). , 1999, The American journal of medicine.

[15]  F. Berenbaum.  Osteoarthritis. Preface. , 2010, Baillière's Best Practice & Research : Clinical Rheumatology.

[16]  R. Willburger,et al.  P362 LUMIRACOXIB SHOWS COMPARABLE EFFICACY AND A FAVOURABLE BLOOD PRESSURE PROFILE COMPARED TO INDOMETHACIN FOR THE TREATMENT OF ACUTE FLARES OF GOUT , 2006 .

[17]  C. Hawkey,et al.  Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  C. Kaeding,et al.  The use of NSAIDs and nutritional supplements in athletes with osteoarthritis: prevalence, benefits, and consequences. , 2005, Clinics in sports medicine.

[19]  G A Green,et al.  Understanding NSAIDs: from aspirin to COX-2. , 2001, Clinical cornerstone.